Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
JACC. Cardiooncology
|
January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
Roberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure
|
April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial
Roberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
JAMA
|
March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial
Emerson C Perin, James T Willerson, Carl J Pepine, et al.
JAMA
|
November 7, 2012
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Circulation Research
|
April 29, 2018
Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit<sup>+</sup> Cardiac Stem Cells As Regenerative Therapy for Heart Failure)
Roberto Bolli, Joshua M Hare, Keith L March, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
JACC. Cardiooncology
|
January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
Roberto Bolli, Emerson C Perin, James T Willerson, et al.
European Journal of Heart Failure
|
April 3, 2021
A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial
Roberto Bolli, Raul D Mitrani, Joshua M Hare, et al.
JAMA
|
March 27, 2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial
Emerson C Perin, James T Willerson, Carl J Pepine, et al.
JAMA
|
November 7, 2012
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
Page
of 11